Merck, a leading science and technology company, has signed a definitive agreement with the intention to acquire HUB Organoids Holding B.V. (HUB). Organoids are cell culture models that functionally resemble an organ. They have the potential to speed up drug development, improve understanding of disease treatment in diverse populations, and reduce the industry’s reliance on animal testing.

领先的科技公司默克公司（Merck）签署了一份最终协议，打算收购HUB Organoids Holding B.V.（HUB）。。它们有可能加速药物开发，提高不同人群对疾病治疗的理解，并减少行业对动物测试的依赖。

HUB is a pioneer in the field of organoids. The company is based in Utrecht, Netherlands and employs around 70 people. Terms of the deal were not disclosed. The transaction is expected to close at the end of December 2024..

HUB是类器官领域的先驱。该公司总部位于荷兰乌得勒支，员工约70人。交易条款未披露。该交易预计于2024年12月底完成。。

“HUB’s leadership in organoids and services strengthen Merck’s already robust portfolio, underscoring our focus on the strategic innovation area of next-generation biology,” said Jean-Charles Wirth, Head of Science & Lab Solutions for the Life Science business of Merck. “For researchers working on novel approaches to treat today’s most challenging diseases, organoids offer critical insights into biologic systems.

默克生命科学业务科学与实验室解决方案主管让·查尔斯·沃思（Jean Charles Wirth）表示：“HUB在类器官和服务方面的领先地位加强了默克已经强大的投资组合，突显了我们对下一代生物学战略创新领域的关注。”。“对于研究治疗当今最具挑战性疾病的新方法的研究人员来说，类器官为生物系统提供了重要的见解。

We look forward making it faster and easier for scientists to get from samples to solutions.”.

我们期待着让科学家更快、更容易地从样本中获取解决方案。”。

HUB possesses the foundational patent portfolio on organoids and has a service offering ranging from new model generation to assay development and high-throughput screening. This adds to and enhances Merck’s portfolio of cell culture reagents, tools and benchtop instruments for academia, biotech, and pharma customers.

HUB拥有类器官的基础专利组合，并提供从新模型生成到分析开发和高通量筛选的服务。这增加并增强了默克公司为学术界、生物技术和制药客户提供的细胞培养试剂、工具和台式仪器的组合。

HUB’s technology enables drug developers to identify and validate potential clinical candidates in a patient-relevant in vitro system, closing the gap between the lab and clinical trials..

HUB的技术使药物开发人员能够在与患者相关的体外系统中识别和验证潜在的临床候选药物，从而缩小实验室与临床试验之间的差距。。

“Our proprietary technology stands at the forefront of solutions that are driving a paradigm shift for drug discovery and development,” said Robert Vries, CEO of HUB Organoids. “Merck’s resources will act as a multiplier for our business. This allows us to significantly expand our reach and increase our impact with customers and, ultimately, patients.”.

HUB Organoids首席执行官罗伯特·弗里斯（RobertVries）表示：“我们的专有技术处于推动药物发现和开发范式转变的解决方案的前沿。”。“默克的资源将成为我们业务的乘数。这使我们能够大大扩大我们的业务范围，并增加我们对客户以及最终患者的影响。”。

The promise of organoids also contributes to Merck’s sustainability, diversity, and inclusion ambitions. The use of organoids may allow researchers to limit their reliance on animal testing by reducing stages in the R&D process, positively contributing to more environmentally sustainable alternatives.

类器官的承诺也有助于默克公司的可持续性、多样性和包容性。类器官的使用可以通过减少研发过程中的阶段来限制研究人员对动物测试的依赖，从而为更具环境可持续性的替代品做出积极贡献。

Organoids also create opportunities for genetically diverse populations to be reflected in research. They allow scientists to better understand drug interactions in patient populations that are underrepresented in clinical trials..

类器官也为遗传多样性人群创造了机会，以反映在研究中。它们使科学家能够更好地了解临床试验中代表性不足的患者群体中的药物相互作用。。

The biology business of Merck’s Science and Lab Solutions business is pioneering innovations in 3D cell culture, a highly attractive market expected to show double digit annual growth over the next decade.[1] The company’s current comprehensive and highly published portfolio of cell biology technologies includes tumor spheroids, stem cell organoids, and tissue engineering via 3D bioprinting.

。[1] 该公司目前全面且高度公开的细胞生物学技术组合包括肿瘤球体，干细胞类器官和通过3D生物打印的组织工程。

Its high-quality cell culture fundamentals and proven downstream analysis reagents offer a complete portfolio for drug development scientists. They include filtration, media, serum, culture plates, cell lines, microbial detection, cytokines and growth factors, analysis tools, transfection reagents, dyes and stains, and antibodies and immunodetection..

其高质量的细胞培养基础和经验证的下游分析试剂为药物开发科学家提供了完整的产品组合。它们包括过滤，培养基，血清，培养板，细胞系，微生物检测，细胞因子和生长因子，分析工具，转染试剂，染料和染色剂，抗体和免疫检测。。

[1] Sources: Human Organoids Market- Global Forecast to 2025 (Markets and Markets), 3D Cell Culture

[1] 来源：人类类器官市场-2025年全球预测（市场和市场），3D细胞培养

Market- Global Forecast to 2028 (Markets and Markets), Organoids Market – Market Size and Forecast (2020-2030), Global and Country Growth Opportunity Analysis (The Insight Partners).

。